Breaking News

Friday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
ACAD Acadia $22.98 1.05 (4.79%) , AGN Allergan $138.99 0.3 (0.22%) … 14:59 02/15/19 02/15 14:59 02/15/19 14:59 Conference/Events	Piper Jaffray specialty pharma analyst to hold analyst/industry conference call » Specialty Pharmaceuticals… Specialty Pharmaceuticals Analysts Amsellem, Brill, Ingerman and Fages discuss the new options of major depressive disorder (MDD) and treatment-resistant depression (TRD) including FDA action on JNJ's intranasal form of esketamine, known as Spravato, and Phase III data for Sage's oral GABA-A modulator SAGE-217 in major depressive disorder (MDD) in 2020, on an Analyst/Industry conference call to be held on February 25 at 1 pm. ACAD Acadia $22.98 1.05 (4.79%) AGN Allergan $138.99 0.3 (0.22%) JNJ Johnson & Johnson $135.76 1.49 (1.11%) SAGE Sage Therapeutics $160.82 2.92 (1.85%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	18 Feb 19 Feb 25 Feb 26 Feb 06 Mar 19 Mar 18 May 28 May

Over a month ago
DLTR Dollar Tree $98.66 5.77 (6.21%) , LLY Eli Lilly $115.98 1.33 (1.16%) … 13:02 01/07/19 01/07 13:02 01/07/19 13:02 On The Fly	Fly Intel: Wall Street's top stories at midday » Stocks opened little… Open Full Text DLTR Dollar Tree $98.66 5.77 (6.21%) LLY Eli Lilly $115.98 1.33 (1.16%) LOXO Loxo Oncology $231.60 91.78 (65.64%) AAPL Apple $147.47 -0.8 (-0.54%) SSNLF Samsung $0.00 (0.00%) AGIO Agios Pharmaceuticals $50.39 3.62 (7.74%) ARQL ArQule $3.34 0.15 (4.70%) ARRY Array BioPharma $17.28 1.57 (9.99%) BPMC Blueprint Medicines $61.96 8.48 (15.86%) KURA Kura Oncology $15.87 0.75 (4.96%) MRTX Mirati Therapeutics $46.85 1.91 (4.25%) LXFT Luxoft $57.50 25.795 (81.36%) DXC DXC Technology $57.53 0.2 (0.35%) SAGE Sage Therapeutics $141.04 43.6 (44.75%) PCG PG&E $18.99 -5.405 (-22.16%) HCLP Hi-Crush Partners $3.67 -0.68 (-15.63%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 08 Jan 14 Jan 17 Jan 28 Jan 10 Feb 19 Mar 18 May
LOXO Loxo Oncology $139.82 8.92 (6.81%) , LLY Eli Lilly $114.65 3.36 (3.02%) … 09:12 01/07/19 01/07 09:12 01/07/19 09:12 Hot Stocks	Fly Intel: Pre-market Movers » HIGHER: Loxo Oncology… HIGHER: Loxo Oncology (LOXO), up 65% after agreeing to be acquired by Eli Lilly (LLY) for $235 per share... Sage Therapeutics (SAGE), up 42% after the SAGE-217 Phase 3 trial met its primary and secondary endpoints... Epizyme (EPZM), up 6% after Leerink analyst Andrew Berens upgraded the stock to Outperform from Market Perform after the company disclosed an agreement with the FDA over plans to seek accelerated approval of tazemetostat in both EZH2 mutant and wild-type follicular lymphoma as part of the same filing based on the current data set... Axsome Therapeutics (AXSM), up 188% after the Phase 2 AXS-05 trial achieved its primary endpoint... Exact Sciences (EXAS), up 8% after pre-announcing Q4 expectations. DOWN AFTER EARNINGS: Commercial Metals (CMC), down 5%. LOWER: Hi-Crush Partners (HCLP), down 20% after suspending its quarterly distribution due to market conditions... Eli Lilly, down 2% after announcing it will acquire Loxo Oncology in deal valued at $8B... British American Tobacco (BTI), down 3% after being downgraded to Market Perform from Outperform at Cowen... PG&E (PCG), down 18% after Reuters report that it is considering filing bankruptcy. LOXO Loxo Oncology $139.82 8.92 (6.81%) LLY Eli Lilly $114.65 3.36 (3.02%) SAGE Sage Therapeutics $97.44 7.93 (8.86%) EPZM Epizyme $7.93 1.94 (32.39%) AXSM Axsome Therapeutics $2.64 -0.01 (-0.38%) EXAS Exact Sciences $65.63 3.63 (5.85%) CMC Commercial Metals $17.08 1.09 (6.82%) HCLP Hi-Crush Partners $4.35 0.33 (8.21%) BTI British American Tobacco $32.99 1.39 (4.40%) PCG PG&E $24.40 0.455 (1.90%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 07 Jan 08 Jan 09 Jan 14 Jan 15 Jan 16 Jan 28 Jan 10 Feb 19 Mar 18 May
SAGE Sage Therapeutics $97.44 7.93 (8.86%) 08:13 01/07/19 01/07 08:13 01/07/19 08:13 Recommendations	Sage Therapeutics analyst commentary at Piper Jaffray » Sage could be up over 50%… Sage could be up over 50% folllowing 'clear win' in PPD, says Piper Jaffray. After Sage Therapeutics reported top-line results from the Phase 3 ROBIN study in women with postpartum depression, or PPD, Piper Jaffray analyst Danielle Brill said the data were "impressive and looked clean across the board" in a note titled "Clear Win as SAGE-217 Knocks It Out of the PPD Park." The analyst, who expects over 50% upside for Sage shares today, keeps an Overweight rating on the stock with a $206 price target. In pre-market trading, Sage Therapeutics shares are up $34.49, or 35%, to $132. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan 19 Mar
SAGE Sage Therapeutics $97.44 7.93 (8.86%) 06:03 01/07/19 01/07 06:03 01/07/19 06:03 Hot Stocks	Sage Therapeutics: SAGE-217 meets primary, secondary endpoints in Phase 3 trial » Sage Therapeutics… Sage Therapeutics reported top-line results from the Phase 3 ROBIN study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression . After two weeks of outpatient treatment, patients treated with SAGE-217 had a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression score, compared to 13.6 for placebo, with statistically significant reductions in HAMD-17 compared to placebo maintained through the end of the four-week follow-up. Remission was achieved in 45% of patients treated with SAGE-217 for two weeks as measured by the HAMD-17 compared with 23% of patients receiving placebo. Results from secondary endpoints were statistically significant and consistent with the primary endpoint. SAGE-217 was generally well-tolerated with a safety profile consistent with that seen in earlier SAGE-217 trials. Overall reports of AEs were similar between SAGE-217 (58%) and placebo (51%). Two subjects experienced serious adverse events, one subject in each group. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan 19 Mar

GILD Gilead $65.89 2.45 (3.86%) , SRPT Sarepta $106.22 -1.22 (-1.14%) … 14:56 01/03/19 01/03 14:56 01/03/19 14:56 On The Fly	Before the Move: Stocks to watch into JPMorgan’s upcoming healthcare conference » Noting that biotech has… Open Full Text GILD Gilead $65.89 2.45 (3.86%) SRPT Sarepta $106.22 -1.22 (-1.14%) SAGE Sage Therapeutics $89.37 -0.08 (-0.09%) CELG Celgene $81.16 14.51 (21.77%) BMY Bristol-Myers $44.72 -7.3 (-14.03%) REGN Regeneron $376.73 4.31 (1.16%) JAZZ Jazz Pharmaceuticals $126.52 1.41 (1.13%) ASND Ascendis Pharma $61.87 -2.93 (-4.52%) IRWD Ironwood $9.98 -0.4 (-3.85%) SLDB Solid Biosciences $28.10 -0.83 (-2.87%) NVAX Novavax $2.04 0.07 (3.55%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	03 Jan 03 Jan 03 Jan 06 Jan 24 Jan 28 Jan 11 Mar 19 Mar 20 Mar 28 Apr 13 May 18 May 20 May 28 May
SAGE Sage Therapeutics $89.06 4.69 (5.56%) 06:05 12/27/18 12/27 06:05 12/27/18 06:05 Recommendations	Sage Therapeutics analyst commentary at Piper Jaffray » Sage's 217 PPD data… Sage's 217 PPD data to be 'important' inflection point in Q1, says Piper Jaffray. Piper Jaffray analyst Danielle Brill told investors in a research note that data from Sage Therapeutics' ongoing trial with 217 in postpartum depression will be an important inflection point for the company in 1Q19 and says she remains bullish ahead of the data. The analyst, who has an Overweight rating and $206 price target on Sage shares, says she is "comfortable" that 217's MOA and PK profiles are very closely related to brex and it should achieve similar anti-depressant effects in the ongoing pivotal PPD trial. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Mar
SAGE Sage Therapeutics $98.74 -3.03 (-2.98%) 16:37 12/18/18 12/18 16:37 12/18/18 16:37 Syndicate	Breaking Syndicate news story on Sage Therapeutics » Sage Therapeutics files… Sage Therapeutics files automatic mixed securities shelf 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Dec 19 Mar
SAGE Sage Therapeutics $100.78 -10.27 (-9.25%) 09:32 12/14/18 12/14 09:32 12/14/18 09:32 Initiation	Sage Therapeutics initiated at Wolfe Research » Sage Therapeutics… Sage Therapeutics initiated with an Outperform at Wolfe Research 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Dec 19 Mar
MRNS Marinus Pharmaceuticals $5.15 -0.03 (-0.58%) , SAGE Sage Therapeutics $102.08 -0.55 (-0.54%) 11:57 12/10/18 12/10 11:57 12/10/18 11:57 Recommendations	Marinus Pharmaceuticals, Sage Therapeutics analyst commentary at JMP Securities » JMP boosts Marinus target… JMP boosts Marinus target to $29, sees 'clear' competitor to Sage Therapeutics. JMP Securities analyst Jason Butler raised his price target for Marinus Pharmaceuticals (MRNS) to $29 from $22 after the company announced positive results for both IV and oral formulations of ganaxolone in postpartum depression. The stock in midday trading is up 1c to $5.18. The results make comparisons to Sage Therapeutics' (SAGE) brexanolone and SAGE-217 relevant, Butler tells investors in a research note. Further, the analyst sees "potentially differentiating attributes" for ganaxolone. Specifically, at 60 hours, the optimal dose cohort for the IV formulation showed a 16.9 point reduction from baseline in HAM-D, and by comparison, in its Phase 3 trial, brexanolone showed a 17.7 point to 19.9 point reduction, explains the analyst. Butler increased his probability of approval for ganaxolone in PPD to 70% from 55%. He believes this morning's results show that Marinus represents a "clear and relevant competitor" to Sage. The analyst reiterates an Outperform rating on Marinus Pharmaceuticals. MRNS Marinus Pharmaceuticals $5.15 -0.03 (-0.58%) SAGE Sage Therapeutics $102.08 -0.55 (-0.54%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Dec 19 Mar

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial